CLAIMS

1. A compound which is represented by formula (I) below

$$R_2 - \underset{\underset{R_2}{|}}{N} - \underset{O}{\overset{||}{C}} - \underset{\underset{R_4}{|}}{N} - R_4$$

with R_1 on the left nitrogen and R_3 on the right nitrogen

(I)

wherein

R_1 is CH_3 or CH_2CH_3;

R_2 is a *para* and/or *meta* substituted phenyl group;

R_3 is H, CH_3 or CH_2CH_3; and

R_4 is a linear or cyclic aliphatic group, which is optionally substituted,

or, wherein

R_1 and R_2 are as stated above while R_3 and R_4 are parts of a 4- to 6-membered cyclic entity, which is optionally substituted,

and which compound has affinity for human IgG of κ-type.

2. A compound according to claim 1, which is an affinity ligand with affinity for the constant region of a Fab fragment of human IgG of κ-type.

3. A compound according to claim 1 or 2, wherein R_1 is CH_3.

4. A compound according to any one of the preceding claims, wherein R_2 comprises a substituted phenyl group and the substituents are selected from the group that consists of F, Cl, Br, I and O.

5. A compound according to any one of the preceding claims, wherein the phenyl group of R_2 is substituted in the *para* position with a group defined as $-O-R_5$, wherein R_5 is either CH_3 or CH_2CH_3.

6. A compound according to any one of the preceding claims, wherein the phenyl group of R_2 is substituted with Cl or F in the *meta* position.

7. A compound according to any one of claims 1-4, wherein the phenyl group of R_2 is substituted with Cl in *meta* and *para* position.

8. A compound according to any one of the preceding claims, wherein R_4 is an aliphatic group, which is interrupted in one or more positions by oxygen atoms.

9. A compound according to any one of the preceding claims, wherein R_4 is an aliphatic group, which comprises one or more carbonyl group.

10. A compound according to any one of the preceding claims, wherein R_4 is an aliphatic group that comprises a terminating functionality selected from the group that consists of a carboxylic acid, nitrogen, oxygen, sulphur or any derivative thereof.

11. A compound according to any one of the preceding claims, wherein R_1 is CH_3; R_2 is a phenyl group that has been substituted with Cl in *meta* and *para* position; and R_3 and R_4 are parts of a cyclic 5-membered group, which is optionally substituted.

12. A compound according to claim 11, wherein the cyclic 5-membered entity is substituted in a position directly adjacent to N with a C(O)-O-CH3 group.

13. A compound according to any one of the preceding claims, which is capable of binding human to the constant region of IgG of κ-type, or a functional derivative thereof, with a binding constant of at least 10^{-3} M.

14. A compound according to any one of the preceding claims, which is capable of binding to the constant region of a human IgG of κ-type, or a functional derivative thereof, via a binding pocket defined by the structure coordinates of the amino acids as shown in Fig 6.

15. Use of a compound according to any one of claims 1-14 for selective binding to the constant region of human IgG of κ-type, or a functional derivative thereof.

16. A sorption complex comprised of a compound according to any one of claims 1-14 directly linked to the constant region of a Fab fragment of a human IgG of κ-type, or a functional derivative thereof.

17. A separation matrix for affinity chromatography, which matrix comprises ligands coupled to a support, wherein the majority of the ligands are compounds as defined in any one of claims 1-14.

18. A separation matrix according to claim 17, wherein the ligands have been coupled to the support via linkers.

19. A separation matrix according to claim 17 or 18, wherein the support is a porous polymeric particle.

20. A generic method of isolating human IgG of κ-type from other components in a liquid, wherein a compound as defined in any one of claims 1-14 or a separation matrix according to any one of claims 17-19 is used.

21. A system suitable for affinity chromatography, which is comprised of a separation matrix as defined in any one of claims 17-19 packed in a column.